## Nol Zahr

## List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/6155983/noel-zahr-publications-by-year.pdf

Version: 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

28 484 12 21 h-index g-index citations papers 676 29 4.7 3.37 L-index avg, IF ext. citations ext. papers

#	Paper	IF	Citations
28	Reversal of immune-checkpoint inhibitor fulminant myocarditis using personalized-dose-adjusted abatacept and ruxolitinib: proof of concept. <b>2022</b> , 10,		2
27	An HPLC assay for the therapeutic drug monitoring of cefiderocol in critically ill patients. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2021</b> , 76, 1643-1646	5.1	2
26	Development and clinical validation of a simple and fast UPLC-ESI-MS/MS method for simultaneous quantification of nine kinase inhibitors and two antiandrogen drugs in human plasma: Interest for their therapeutic drug monitoring. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , <b>2021</b> , 197, 11396	3.5 58	4
25	Efficacy and safety of mexiletine in non-dystrophic myotonias: A randomised, double-blind, placebo-controlled, cross-over study. <i>Neuromuscular Disorders</i> , <b>2021</b> ,	2.9	4
24	Simple and accurate quantitative analysis of cefiderocol and ceftobiprole in human plasma using liquid chromatography-isotope dilution tandem mass spectrometry: interest for their therapeutic drug monitoring and pharmacokinetic studies. <i>Clinical Chemistry and Laboratory Medicine</i> , <b>2021</b> , 59, 18	5.9 <b>00-181</b>	0 2
23	Pharmacokinetics and pharmacodynamics of hydroxychloroquine in hospitalized patients with COVID-19. <i>Therapie</i> , <b>2021</b> , 76, 285-295	3.8	3
22	Ciprofloxacin population pharmacokinetics during long-term treatment of osteoarticular infections. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2021</b> , 76, 2906-2913	5.1	2
21	Mycophenolic acid area under the curve in patients with inflammatory myopathies. <i>Rheumatology</i> , <b>2021</b> , 60, 3026-3028	3.9	О
20	Evaluation of Hydroxychloroquine Blood Concentrations and Effects in Childhood-Onset Systemic Lupus Erythematosus. <i>Pharmaceuticals</i> , <b>2021</b> , 14,	5.2	3
19	Anti-Interleukin-6 and Janus Kinase Inhibitors for Severe Neurologic Toxicity of Checkpoint Inhibitors. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , <b>2021</b> , 8,	9.1	3
18	Development and validation of a UPLC-MS/MS method for simultaneous quantification of levofloxacin, ciprofloxacin, moxifloxacin and rifampicin in human plasma: Application to the therapeutic drug monitoring in osteoarticular infections. <i>Journal of Pharmaceutical and Biomedical</i>	3.5	8
17	Hydroxychloroquine to Prevent Recurrent Congenital Heart Block in Fetuses of Anti-SSA/Ro-Positive Mothers. <i>Journal of the American College of Cardiology</i> , <b>2020</b> , 76, 292-302	15.1	38
16	Electrocardiographic QT Intervals in Infants Exposed to Hydroxychloroquine Throughout Gestation. <i>Circulation: Arrhythmia and Electrophysiology</i> , <b>2020</b> , 13, e008686	6.4	6
15	Sirolimus and mTOR Inhibitors: A Review of Side Effects and Specific Management in Solid Organ Transplantation. <i>Drug Safety</i> , <b>2019</b> , 42, 813-825	5.1	40
14	A Prospective International Study on Adherence to Treatment in 305 Patients With Flaring SLE: Assessment by Drug Levels and Self-Administered Questionnaires. <i>Clinical Pharmacology and Therapeutics</i> , <b>2019</b> , 106, 374-382	6.1	20
13	Effect of topiramate on eating behaviours in Prader-Willi syndrome: TOPRADER double-blind randomised placebo-controlled study. <i>Translational Psychiatry</i> , <b>2019</b> , 9, 274	8.6	18
12	Development and Validation of a Fast Ultra-High Performance Liquid Chromatography-Fluorescent Method for the Quantification of Hydroxychloroquine and Its Metabolites in Patients With Lupus. <i>Therapeutic Drug Monitoring</i> , <b>2019</b> , 41, 476-482	3.2	10

## LIST OF PUBLICATIONS

11	pharmacokinetics in ventilator-associated pneumonia caused by MDR bacteria. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2018</b> , 73, 1639-1646	5.1	6	
10	Prevention of Invasive Aspergillus Fungal Infections with the Suspension and Delayed-Release Tablet Formulations of Posaconazole in Patients with Haematologic Malignancies. <i>Scientific Reports</i> , 2018, 8, 1681	4.9	12	
9	A Prospective International Study on Adherence to Treatment in 305 Patients With Flaring SLE: Assessment by Drug Levels and Self-Administered Questionnaires. <i>Clinical Pharmacology and Therapeutics</i> , <b>2018</b> , 103, 1074-1082	6.1	24	
8	The effect of increasing the dose of hydroxychloroquine (HCQ) in patients with refractory cutaneous lupus erythematosus (CLE): An open-label prospective pilot study. <i>Journal of the American Academy of Dermatology</i> , <b>2016</b> , 74, 693-9.e3	4.5	44	
7	Infliximab improves endothelial dysfunction in a mouse model of antiphospholipid syndrome: Role of reduced oxidative stress. <i>Vascular Pharmacology</i> , <b>2015</b> , 71, 93-101	5.9	14	
6	The functional dlt operon of Clostridium butyricum controls the D-alanylation of cell wall components and influences cell septation and vancomycin-induced lysis. <i>Anaerobe</i> , <b>2015</b> , 35, 105-14	2.8	10	
5	Simultaneous determination of rivaroxaban and dabigatran levels in human plasma by high-performance liquid chromatography-tandem mass spectrometry. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , <b>2014</b> , 100, 230-235	3.5	29	
4	Dopa-decarboxylase gene polymorphisms affect the motor response to L-dopa in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , <b>2014</b> , 20, 170-5	3.6	36	
3	Dramatic response of a BRAF V600E-mutated primary CNS histiocytic sarcoma to vemurafenib. <i>Neurology</i> , <b>2014</b> , 83, 1478-80	6.5	47	
2	Mycophenolic acid area under the curve correlates with disease activity in lupus patients treated with mycophenolate mofetil. <i>Arthritis and Rheumatism</i> , <b>2010</b> , 62, 2047-54		61	
1	Pharmacokinetic study of mycophenolate mofetil in patients with systemic lupus erythematosus and design of Bayesian estimator using limited sampling strategies. <i>Clinical Pharmacokinetics</i> , <b>2008</b> , 47, 277-84	6.2	36	